Breast Cancer Control Policy

Objectives

The policy establishes a nationally applicable framework for breast cancer control in South Africa, aiming to reduce morbidity and mortality, improve survival and quality of life, and ensure equitable, timely access to awareness, early detection, diagnosis, treatment, survivorship care and palliation.[1]It aligns breast cancer prevention and control with Sustainable Development Goal 3, South Africa’s National Development Plan 2030, National Health Insurance reform and related women’s, reproductive and chronic-disease health services.[2][3]

• Improve early recognition and presentation through community education, health-worker training, breast-health awareness and opportunistic clinical breast examination in primary care.[1][4]
• Reduce diagnostic and treatment delays through defined referral pathways, rapid access to specialist assessment, triple assessment and coordinated staging.[5][6]
• Provide nationally applicable standards of care regardless of geographical location or social circumstances, while allowing provinces to adopt service models suited to local capacity and population needs.[7]
• Ensure access to a network of Specialist Breast Units and Provincial Oncology Units providing multidisciplinary diagnosis, surgery, systemic therapy, radiotherapy, supportive care and palliative care.[1][5]
• Apply risk-adapted assessment, screening and genetic services for women with familial or inherited susceptibility to breast and ovarian cancer.[8][9][10]
• Improve survivorship through psychosocial support, follow-up, surveillance, reconstruction options, lymphoedema care and cost-effective avoidance of unnecessary testing in asymptomatic patients.[11][12][13][14]
• Strengthen monitoring, research and community engagement through cancer registries, facility data, civil-society participation and auditing of care standards and outcomes.[1][15]

Implementation

Implementation is organised as an integrated, multidisciplinary pathway across community, primary, district, regional, tertiary, quaternary and private services.[3][7]The delivery model centres on Specialist Breast Units as accessible hubs for rapid diagnosis, breast-disease management, staff training, outreach, survivorship support, palliative-care coordination and audit, linked with Provincial Oncology Units for specialised chemotherapy, radiotherapy and advanced oncology services.[5][16]

• Establish and upgrade designated Specialist Breast Units with minimum staffing and equipment, multidisciplinary capability, triage-based access to specialist assessment within 21 to 45 days, and formal links with Provincial Oncology Units.[5]
• Enable direct, bidirectional referral between primary care, district hospitals, Specialist Breast Units and Provincial Oncology Units, including referral to another province where required services are unavailable locally.[16][17]
• Train primary healthcare nurses and district clinicians in breast health and systematic examination, and use open-access regional breast clinics, standardised referral forms, transfer protocols, patient transport and patient navigation to reduce barriers to care.[18][19]
• Deliver triple assessment for symptomatic breast disease through clinical examination, appropriate imaging and pathology, using image-guided core biopsy as the diagnostic standard where appropriate and standardised synoptic pathology reports to guide management.[20][21][22]
• Coordinate treatment through multidisciplinary teams involving breast surgeons, oncologists, radiologists, pathologists, oncology nurses, psychosocial and rehabilitation staff, genetic services, palliative-care professionals and other relevant specialists.[7][23]
• Provide risk-stratified genetic counselling, testing, specialist referral and imaging-based screening for women with relevant family histories or known susceptibility mutations, while recognising limited access to comprehensive genetic testing.[24][10]
• Deliver treatment according to tumour stage, biology, recurrence risk, co-morbidities and patient preferences, including surgery, reconstruction, endocrine therapy, chemotherapy, biological therapy, radiotherapy and treatment for metastatic disease.[12][25][26][27]
• Assign named breast care nurses or navigators to support communication, care coordination and follow-up, with lay counsellors from non-profit organisations supporting navigation where specialist nursing capacity is limited.[11]
• Integrate palliative care early alongside standard cancer treatment, strengthen access to affordable opioids, trained personnel and home-care programmes, and refer complex physical or psychosocial needs to specialist services.[13]
• Collect electronic patient information from diagnosis throughout the disease course, allocate data-management responsibility for quality assurance and audit, and use registry, stage, tumour-size, survival and treatment-timeline data to inform service improvement.[15]
• Engage civil-society organisations, non-governmental organisations, community healthcare workers and community leaders in education, counselling, peer support, referral information and culturally appropriate awareness activities.[15][28]

Monitoring & Evaluation

The policy establishes a national monitoring and evaluation framework for breast cancer control, combining standards-based auditing, facility data, cancer registration, clinical quality assurance and service-timeline measures. It aims to assess implementation, intervention impact, care quality, equity and outcomes, but does not provide a complete national indicator dictionary, reporting calendar or formal accountability schedule.[1][7][15]

• Use standards of care and associated key performance indicators to support continuous audits in breast cancer facilities and coordination within and between provinces.[7]
• Collect information from diagnosis throughout the disease course, enter it electronically, and assign data managers to support data quality, ethical use and audit requests.[15]
• Use breast cancer registries, population-based cancer registries and mortality registers to produce incidence and mortality statistics for policy formulation and reassessment.[15]
• Record stage, tumour size at diagnosis, survival by stage and treatment timelines to assess disease burden, treatment quality and health-system improvement.[15]
• Address data limitations, as incidence is described as under-reported, the National Cancer Registry is pathology-based rather than population-based, and available registry data are not current.[1]
• Audit referral forms, patient pathways, treatment records and implemented standards through Specialist Breast Units and coordinated computerised breast-care software.[16][17]
• Monitor service timeliness, including diagnostic work-up within two weeks at Specialist Breast Units and Provincial Oncology Units, diagnosis-positive treatment within 60 days of first presentation, and first definitive treatment within 31 days of the decision to treat.[19][6]
• Track clinical performance measures, including completion of triple assessment within 21 days for more than 80% of patients, referral timeliness, genetic-service uptake, annual screening among eligible mutation carriers, and neoadjuvant-treatment initiation within 30 days of diagnosis.[29][30][5][31]
• Monitor radiotherapy timing through simulation within 60 days and treatment completion within 120 days.[32]
• Maintain laboratory internal and external quality-assurance systems, including daily immunohistochemistry checks and quality assurance for hormone-receptor and human epidermal growth factor receptor 2 testing.[21][22]
• Maintain specialised breast-unit registries and audit databases that record referral source, diagnosis, pathology, treatment, outcomes and intervals from presentation to diagnosis and first multidisciplinary-team visit; target completion of definitive diagnosis and first team visit within four weeks.[33]
• Use regular clinical follow-up and annual mammography where residual breast tissue remains, while avoiding routine blood tests and diagnostic imaging for asymptomatic patients.[14]

Several monitoring and evaluation identifiers are listed, including ME1, ME2, ME7 and ME12 to ME22, but the supplied material does not consistently define their indicators, targets, reporting responsibilities or escalation mechanisms.[34][5][20][12][35]

Costing & Financing

The policy recognises that breast cancer control requires sustained investment in specialised services, diagnostics, medicines, workforce, data systems, transport and community support. It provides no overall programme budget, quantified funding gap, financing plan, allocation by province or economic model.[5][16][15]

• Provide a specialised budget for chemotherapy and biological therapies at Provincial Oncology Unit level.[19]
• Resource Specialist Breast Units with trained staff, equipment, imaging, biopsy and pathology services, surgical capacity, referral systems, patient transport, navigators and computerised data systems.[5][18][19]
• Recognise that mammography requires substantial financial and workforce resources, and introduce population screening only where resources can support reliable coverage of at least 70% of women aged 50 years and older.[34]
• Prioritise affordable and sustainable screening approaches; annual clinical breast examination by ancillary health workers for women aged 40 to 60 years is cited as potentially nearly as effective as biennial mammography in developing countries at substantially lower cost.[36]
• Support affordable opioid access, trained palliative-care personnel and home-care programmes, with home palliative care described as feasible and cost-effective in lower-resource and remote rural settings.[13]
• Use cost-effective follow-up by relying on clinical review and annual mammography where indicated, rather than routine blood tests and imaging in asymptomatic patients.[13][14]
• Recognise that affordability and availability influence hormonal treatment selection and access to human epidermal growth factor receptor 2-targeted therapy, whose cost limits access internationally and in South Africa.[26][37]
• Deliver structured screening counselling free of charge at primary healthcare facilities, community health centres and designated screening and diagnostic units; educational campaigns may be implemented at low or minimal cost.[28]
• Use National Health Insurance as a health-financing reform intended to support affordable, quality services according to health need rather than socio-economic status, although no breast-cancer-specific allocation is specified.[3]

Economic evidence remains limited in several areas: the cost-effectiveness of emerging breast-imaging technologies has not been determined, and no monetary costs are given for genetic services, radiotherapy, surgery, systemic therapies, palliative care or registry functions.[29][24][27]